What medications can be used to treat cannabis hyperemesis syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medications for Cannabis Hyperemesis Syndrome Treatment

Dopamine receptor antagonists like haloperidol (0.5-2 mg IV or PO every 4-6 hours) are the first-line pharmacological treatment for cannabis hyperemesis syndrome, though complete cannabis cessation remains the only definitive cure. 1

First-Line Treatment Options

  1. Dopamine receptor antagonists:

    • Haloperidol: 0.5-2 mg IV or PO every 4-6 hours 1
    • Droperidol: effective alternative to haloperidol 1, 2
    • Monitor for QT interval prolongation and acute dystonic reactions 1
  2. Non-pharmacological interventions:

    • Hot showers/baths (provide temporary relief) 1
    • Topical capsaicin cream applied to abdomen 1, 3
    • IV fluid rehydration 1
    • Quiet, darker room environment 1

Second-Line Treatment Options

  1. Antiemetics:

    • Ondansetron, promethazine, or prochlorperazine 1
    • Note: Traditional antiemetics often have limited efficacy in CHS 3, 4
  2. Sedation strategies:

    • Benzodiazepines: lorazepam 0.5-2 mg PO/SL/IV every 6 hours, alprazolam 1, 3
    • Olanzapine: 5-10 mg PO daily 1
  3. Pain management:

    • Non-narcotic pain control: IV ketorolac 1
    • Avoid opioids as they may worsen symptoms and are not recommended as first-line therapy 1, 2
  4. Other options:

    • Corticosteroids 1

Treatment Algorithm

  1. Initial management:

    • Confirm diagnosis (cyclic vomiting in cannabis user >1 year, use >4 times/week, relief with hot showers) 1
    • Rule out life-threatening conditions
    • Basic workup: CBC, electrolytes, glucose, liver function tests, lipase, urinalysis 1
  2. Acute symptom management:

    • Start IV fluid rehydration
    • Administer haloperidol 0.5-2 mg IV or PO every 4-6 hours 1
    • Apply topical capsaicin cream to abdomen 1
    • Encourage hot showers/baths for temporary relief 1
  3. If inadequate response:

    • Add benzodiazepines (lorazepam 0.5-2 mg) 1, 3
    • Consider olanzapine 5-10 mg 1
    • Try conventional antiemetics (ondansetron, promethazine) 1
  4. Long-term management:

    • Complete cannabis cessation for at least 3-6 months 1
    • Patient education about recurrence with resumed cannabis use 1

Important Clinical Considerations

  • CHS is frequently unrecognized, leading to unnecessary testing and treatment 3
  • Recovery typically takes 1-2 days after appropriate treatment and cannabis cessation 1
  • Symptoms almost always recur if cannabis use is reinitiated 1
  • Benzodiazepines and antipsychotics appear most efficacious due to their sedating effects 5
  • Avoid narcotic pain medications as they may worsen symptoms 1
  • Patients should be counseled that complete cannabis cessation is the only definitive treatment 1, 4

Pitfalls to Avoid

  • Failing to recognize CHS, leading to extensive unnecessary testing
  • Relying solely on traditional antiemetics, which often fail in CHS 3, 4
  • Using opioids as first-line therapy, which may worsen symptoms 2
  • Not emphasizing cannabis cessation as the definitive treatment 1, 4
  • Overlooking the effectiveness of simple measures like hot showers and topical capsaicin 1

References

Guideline

Cannabinoid Hyperemesis Syndrome Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Managing cannabinoid hyperemesis syndrome in adult patients in the emergency department.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025

Research

Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.